The Medical University of South Carolina Becomes First in South Carolina to Adopt MOLLI Surgical's Advanced Breast Cancer Technology

MOLLI® 2 System offers breast cancer patients enhanced comfort and unmatched surgical precision CHARLESTON, S.C. and DEERFIELD, Ill.

, July 25, 2024 /PRNewswire/ -- MUSC Hollings Cancer Center, an NCI-designated cancer center within the Medical University of South Carolina (MUSC), the state's only comprehensive academic health system, is partnering with MOLLI Surgical to adopt the MOLLI® 2 System. The award-winning wire-free and radiation-free technology for localizing lesions for breast cancer surgery improves the patient experience and has earned praise from surgeons for its accuracy and ease of use. "Hollings has adopted the MOLLI 2 System in order to treat our patients with the most accurate, advanced technology available," said Andrea Abbott , M.

D., a surgical oncologist and medical director of the Comprehensive Breast Program at Hollings. "MOLLI 2 provides precise feedback while localizing the lesion; the information is instantaneous and allows for efficiency and accuracy.

And patients appreciate the flexibility of having the MOLLI® Marker placed ahead of time instead of adding another procedure to the day of surgery." The MOLLI 2 System is an innovative technology that allows radiologists to mark lesions with the MOLLI Marker, a localization device roughly the size of a sesame seed. The device can be placed up to 30 days before surgery, allowing radiology to make the best use of time in the mammography suite without the need to synchronize schedules with surgery.

Su.